Literature DB >> 8165853

Comparison of systemic and mucosal priming for mucosal immune responses to a bacterial protein antigen given with or coupled to cholera toxin (CT) B subunit, and effects of pre-existing anti-CT immunity.

H Y Wu1, M W Russell.   

Abstract

Intraperitoneal immunization with a bacterial protein antigen conjugated to cholera toxin B subunit (CTB) was generally less effective than intragastric or intranasal immunization in generating mucosal IgA antibodies, and in priming the mucosal immune system to respond to intragastric or intranasal boosting. Previous intragastric or intranasal immunization which generated high levels of mucosal and circulating antibodies to CTB did not suppress mucosal IgA responses induced by intragastric or intranasal immunization with bacterial antigen conjugated to or mixed with CTB, but serum antibody responses were inhibited depending on the route of immunization and whether CTB was conjugated to or mixed with the antigen.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8165853     DOI: 10.1016/0264-410x(94)90197-x

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  9 in total

1.  Targeting of nasal mucosa-associated antigen-presenting cells in vivo with an outer membrane protein A derived from Klebsiella pneumoniae.

Authors:  L Goetsch; A Gonzalez; H Plotnicky-Gilquin; J F Haeuw; J P Aubry; A Beck; J Y Bonnefoy; N Corvaïa
Journal:  Infect Immun       Date:  2001-10       Impact factor: 3.441

2.  Monoclonal antibody-mediated modulation of the humoral immune response against mucosally applied Streptococcus mutans.

Authors:  L J Brady; M L van Tilburg; C E Alford; W P McArthur
Journal:  Infect Immun       Date:  2000-04       Impact factor: 3.441

3.  Limited local and systemic antibody responses to Neisseria gonorrhoeae during uncomplicated genital infections.

Authors:  S R Hedges; M S Mayo; J Mestecky; E W Hook; M W Russell
Journal:  Infect Immun       Date:  1999-08       Impact factor: 3.441

4.  Intranasal administration of a synthetic lipopeptide without adjuvant induces systemic immune responses.

Authors:  Lbachir BenMohamed; Radhika Krishnan; Catherine Auge; James F Primus; Don J Diamond
Journal:  Immunology       Date:  2002-05       Impact factor: 7.397

5.  Evaluation of formalin-inactivated Clostridium difficile vaccines administered by parenteral and mucosal routes of immunization in hamsters.

Authors:  J F Torres; D M Lyerly; J E Hill; T P Monath
Journal:  Infect Immun       Date:  1995-12       Impact factor: 3.441

6.  Development of Safe and Non-Self-Immunogenic Mucosal Adjuvant by Recombinant Fusion of Cholera Toxin A1 Subunit with Protein Transduction Domain.

Authors:  Byoung-Shik Shim; In Su Cheon; Eugene Lee; Sung-Moo Park; Youngjoo Choi; Dae-Im Jung; Eunji Yang; Jung-Ah Choi; June Young Chun; Jae-Ouk Kim; Cheol-Heui Yun; Cecil Czerkinsky; Man Ki Song
Journal:  J Immunol Res       Date:  2018-03-07       Impact factor: 4.818

7.  Active immunity and T-cell populations in pigs intraperitoneally inoculated with baculovirus-expressed transmissible gastroenteritis virus structural proteins.

Authors:  K Sestak; R K Meister; J R Hayes; L Kim; P A Lewis; G Myers; L J Saif
Journal:  Vet Immunol Immunopathol       Date:  1999-09-20       Impact factor: 2.046

8.  Formulation and delivery of vaccines: Ongoing challenges for animal management.

Authors:  Sameer Sharma; Lyn A Hinds
Journal:  J Pharm Bioallied Sci       Date:  2012-10

9.  The Quest for an HIV-1 Vaccine Adjuvant: Bacterial Toxins as New Potential Platforms.

Authors:  Toufic O Nashar
Journal:  J Clin Cell Immunol       Date:  2014-07-17
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.